Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of BI 894416 Fed vs Fasted in Healthy Males
NCT03871595Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Mar 2019
- Primary completion
- Apr 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of BI 894416 in asthma (2 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Area Under the Concentration-time Curve of BI 894416 in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point and Maximum Measured Concentration of BI 894416 in Plasma. Started Mar 2019; status: completed.
02
Drugs
BI 894416
03
Conditions
asthma
Beyond the preview
Go deeper on NCT03871595.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03871595.